JAZZ vs. UTHR: Jazz Pharmaceuticals vs. United Therapeutics Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while UTHR is classified in Biotechnology.
| Profile Item | JAZZ | UTHR |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | United Therapeutics Corporation |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Biotechnology |
| GICS Sub-Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 15.07 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2007 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Total Return (1Y) | 84.44% | 28.77% |
| Total Return (3Y, Annualized) | 27.57% | 37.63% |
| Total Return (5Y, Annualized) | 12.88% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 35.00% |
| Beta (5Y) | 0.33 | 0.49 |
| Max Drawdown (5Y) | -42.03% | -33.00% |
| Avg. Volume (3M) | 878.80K | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.70 |
| Sortino Ratio (1Y) | 4.14 | 1.29 |
Profitability
ROE (TTM)
United Therapeutics (UTHR) at 19.13% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for UTHR.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| ROE (TTM) | 5.05% | 19.13% |
| ROA (TTM) | 6.92% | 10.91% |
| Net Margin (TTM) | 4.37% | 38.61% |
| Operating Margin (TTM) | 30.17% | 28.99% |
| Gross Margin (TTM) | 91.10% | 86.34% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
United Therapeutics (UTHR) at 13.07% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 10.61% |
| Revenue Growth (3Y CAGR) | 5.26% | 18.02% |
| EPS Growth (YoY) | -167.51% | 13.07% |
| EPS Growth (3Y CAGR) | -- | 22.92% |
Financial Strength
Current Ratio (MRQ)
United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Jazz Pharmaceuticals (JAZZ) carries debt-to-equity ratio of 1.35 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 4.61 |
| Debt / Equity (MRQ) | 1.35 | -- |
| Net Debt / EBITDA | 1.39 | -1.53 |
Dividends
Dividend Yield (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
United Therapeutics (UTHR) at 21.22 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | UTHR |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 21.22 |
| P/S Ratio (TTM) | 3.19 | 7.51 |
| P/B Ratio (MRQ) | 3.59 | 3.80 |
| Free Cash Flow Yield (TTM) | 11.16% | 1.90% |